Semaglutide is the most extensively researched GLP-1 receptor agonist, with data spanning metabolic, cardiovascular, and emerging neurological research. This article reviews the SUSTAIN, STEP, and SELECT research programs and their key findings.
Tirzepatide is a dual GLP-1/GIP receptor agonist that has generated one of the largest bodies of clinical research data among modern metabolic peptides. This review examines key findings from the SURPASS and SURMOUNT research programs.
Retatrutide is a triple agonist peptide engaging GLP-1, GIP, and glucagon receptors simultaneously. This article reviews what current Phase 2 and Phase 3 clinical research reveals about its metabolic effects and mechanism of action.
